Latest news with #Viaskin
Yahoo
2 days ago
- Business
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
03-06-2025
- Business
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Combined General Meeting of June 11, 2025
Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), will hold its Combined General Meeting (the 'General Meeting') on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company's headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French 'Bulletin des Annonces Légales Obligatoires (BALO)' dated May 07, 2025 (No. 2501507). The meeting notice (avis de convocation) will be published in the BALO and in the legal newspaper Affiches parisiennes on May 21, 2025. The information and preparatory documents for this General Meeting are available to the Company's shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company's website ( Any shareholder wishing to receive these documents by post or electronically may make a request until midnight, Paris time, on June 06, 2025 (i.e., the fifth day before the General Meeting) by contacting the Company at investors@ For bearer shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an intermediary, in accordance with Article L. 211-3 of the French Monetary and Financial Code. Webcast of the Annual General Meeting A live webcast of the General Meeting will be available on the Company's website at the following address: 2025 Annual General Meeting | DBV Technologies The recorded webcast of the General Meeting will be disclosed no later than seven (7) business days after the date of the General Meeting and will remain accessible on the Company's website for at least the minimum legal and regulatory period from its publication online. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-03-2025
- Business
- Yahoo
Novo gains Lexicon obesity drug; CRISPR COO to step down
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Novo Nordisk and DBV Technologies, as well as updates from Arbutus Biopharma, Bicycle Therapeutics and CRISPR Therapeutics that you may have missed. Novo Nordisk on Friday licensed an experimental medicine from Lexicon Pharmaceuticals that it intends to develop for obesity and associated metabolic disorders. Lexicon is receiving $45 million in cash upfront, which it will use to pay down debt, according to a regulatory filing. It could also get up to $960 million in future payouts if certain milestones are met. The drug, LX9851, works differently than most obesity medicines and in preclinical testing appeared to boost the effects of semaglutide, the active ingredient in Novo's weight loss therapy Wegovy. — Ben Fidler DBV Technologies has secured up to $307 million in financing to support the potential U.S. approval and commercial launch of a skin patch it's been developing for peanut allergies. The funding was led by more than eight investment firms, among them MPM BioImpact and Vivo Capital, and comes days after the company and the Food and Drug Administration agreed on the safety data required for an approval submission. DBV expects to generate that data from an ongoing Phase 3 trial and file an application next year. The FDA rejected DBV's skin patch, Viaskin, in 2020. — Ben Fidler Arbutus Biopharma will lay off 57% of its workforce and halt in-house scientific research as part of a strategic review undertaken by new CEO Lindsay Androski. Arbutus revealed the job cuts, along with the departures of three senior executives, in an earnings report Thursday. The company is also reviewing the development plans for a pair of hepatitis B medicines in clinical testing, and expects to provide an update on the next steps for both once the evaluation is complete. Androski was named CEO during a board shake-up in February that included the appointment of four new directors, among them Roivant Sciences CEO Matt Gline. — Ben Fidler Bicycle Therapeutics chairman Pierre Legault is retiring and will be replaced by Felix Baker, the cofounder of hedge fund Baker Brothers, the cancer drug developer said Thursday. Bicycle announced the switch alongside several other changes to its board of directors and leadership team. Transgene CEO Alessandro Riva has joined the board along with Baker, while medical oncologist Fabrice André was named on the company's clinical advisory board. In addition, Eric Westin and Jim MacDonald-Clink were promoted to chief medical officer and head of business development, respectively, following the transitions of Santiago Arroyo and Nigel Crockett to advisory roles. The changes "strengthen our expertise in oncology," said CEO Kevin Lee, in a statement. Bicycle has lost about two-thirds of its market value over the last year. — Ben Fidler Julianne Bruno, the chief operating officer of CRISPR Therapeutics, is stepping down on April 11 to "pursue external opportunities," the company said Wednesday. Bruno joined CRISPR in 2019, became COO last year and "has been instrumental" in advancing the company's hematology and oncology programs, CEO Samarth Kulkarni said in a statement. With partner Vertex Pharmaceuticals, CRISPR brought to market the gene editing treatment Casgevy for sickle cell and beta thalassemia. It also has two cancer treatments in clinical testing. — Ben Fidler Sign in to access your portfolio
